On long hunt for off-the-shelf CAR-T, Cel­lec­tis woos biotech chief to be­come its CFO

Cel­lec­tis has raid­ed an un­usu­al place for its new CFO: a fel­low gene en­gi­neer­ing start­up’s cor­ner of­fice.

The French biotech, which is known for cell and gene ther­a­pies cre­at­ed on its TAL­EN tech­nol­o­gy plat­form, has ap­point­ed Bing Wang, up un­til now the CEO of Refuge Biotech­nolo­gies, as its top num­bers guy and mem­ber of its ex­ec­u­tive com­mit­tee.

Wang’s ré­sumé fits right in­to Cel­lec­tis’ pro­file: Be­fore co-found­ing Refuge, he spent near­ly a decade as an in­vest­ment banker, head­ing up the health­care team at Bar­clay’s and help­ing mul­ti­ple com­pa­nies raise cap­i­tal. And at Refuge, he was charged with steer­ing a slate of CRISPR-in­spired CAR-T, which car­ries gene mod­u­la­tions in ad­di­tion to the CAR, in­to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER